Market Size
The global vagus nerve stimulators market was valued at USD 742.16 million in 2025 and is projected to reach nearly USD 1.86 billion by 2033, growing at a CAGR of 12.6% during the forecast period from 2026 to 2033.
The market is witnessing significant growth driven by the rising prevalence of neurological disorders such as epilepsy, depression, migraine, and treatment resistant psychiatric conditions, along with increasing demand for minimally invasive neuromodulation therapies. Growing adoption of implantable and non invasive vagus nerve stimulation devices for chronic disease management is significantly improving patient outcomes and supporting market expansion globally. In addition, increasing awareness regarding bioelectronic medicine, expanding applications of neuromodulation technologies, and rising healthcare investments in advanced neurological care are further accelerating market growth.
Market Summary
| Metrics | Details |
| Market CAGR | 12.6% |
| Segments Covered | By Product, By Application, By End-User, By Biomaterial, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For more insights Request Free Sample
Market Trends
The global market for the vagus nerve stimulators market is primarily driven by rising prevalence of neurological disorders, growing demand for advanced medical devices for the treatment, and increasing investment of biotechnology and pharmaceutical industries in R&D.
Neurological disorders are an emerging challenge to health care systems globally, requiring further study, government and social engagement, and improvements in health care infrastructure. According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years. Neurological disorders contribute to 92 million DALYs in 2005 projected to increase to 103 million in 2030 (approx. a 12% increase). While Alzheimer and other dementias are projected to show a 66% increase from 2005 to 2030, there is an estimated 57% decrease in DALYs associated with poliomyelitis, tetanus, meningitis, and Japanese encephalitis combined.
However, higher cost of the stimulator devices and treatment is restraining the growth of the vagus nerve stimulators market. For instance, according to Epilepsy Foundation, VNS therapy currently costs approximately 30,000 US$, which includes the implant and surgical procedure and is highly uneconomical for the people/patients living in low-income economies.
Market Segmentation Analysis
On the basis of type, the implantable VNS devices accounted for the largest market share in 2018 and are expected to remain dominant over the forecast period, 2019-2026. Implantable VNS devices are the highest revenue-generating segment in vagus nerve stimulator market as the vagus nerve stimulator implanted devices are currently being approved for the treatment of refractory epilepsy and depression only. Additionally, results from many ongoing clinical studies are in pipeline. The use of implantable vagus nerve stimulators is associated with major complications such as cardiac dysrhythmias, both at the time of implantation and post-operative implantation. After examining the effects in 130 patients implanted with vagus nerve stimulators between 2000 and 2013, it was observed that the response rate increased from 22.1% to 43.8% from the first to the fifth year after implantation.
By application, Epilepsy held the largest market share in 2018. According to WHO (World Health Organization), more than 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally, and nearly 80% of people with epilepsy live in low- and middle-income countries in 2019. For the treatment of epilepsy, the demand for VNS devices is increasing. For instance, in Sept 2018, a new system of vagus nerve stimulation (VNS) therapy was implanted in the first patient with drug-resistant epilepsy, as part of a global registry launched by LivaNova to evaluate the treatment in a real-world setting.
Market Geographical Share
The North America region occupied the largest market share of the global vagus nerve stimulators market in 2018 and is expected to remain dominant over the forecast period, due to an increase in the advanced healthcare systems along with ease of availability of medical devices.
Europe and Asia Pacific are also growing rapidly with growing market value over the forecast period. Owing increased government support and high awareness among consumers for advanced healthcare and research in medicine are driving the growth of the vagus nerve stimulators market in Europe. Asia Pacific market is growing at a high CAGR over the forecast period due to rising incidence of neurological disorders of various types in this region. In addition, governments in emerging economies are increasingly extending support for advanced healthcare practices, hence fuelling the demand for vagus nerve stimulators in this region.
Key Developments
February 2026: Rising adoption of implantable and non-invasive neuromodulation technologies accelerated innovation in the global Vagus Nerve Stimulators market. Healthcare providers increasingly utilized vagus nerve stimulation therapies for epilepsy, treatment-resistant depression, chronic pain, and inflammatory disorders.
January 2026: Increasing investments in bioelectronic medicine, AI-enabled neuromodulation platforms, and wearable neurostimulation devices strengthened development of advanced vagus nerve stimulation technologies worldwide. Companies expanded integration of digital monitoring, remote therapy management, and personalized stimulation protocols to improve patient outcomes.
December 2025: Growing clinical research activities and rising regulatory support accelerated commercialization of next-generation vagus nerve stimulator devices globally. Research organizations intensified focus on minimally invasive and transcutaneous stimulation technologies designed to improve therapeutic accessibility and patient comfort.
November 2025: Expansion of neurology and mental healthcare infrastructure across North America, Europe, and Asia-Pacific strengthened accessibility to vagus nerve stimulation therapies. Healthcare systems increasingly adopted neuromodulation approaches for neurological disorders including epilepsy, depression, migraine, and anxiety-related conditions.
October 2025: Rising advancements in machine learning, predictive analytics, and neurophysiological monitoring improved precision and personalization in vagus nerve stimulation therapies globally. Research institutions accelerated development of EEG-guided and biomarker-based neuromodulation strategies supporting optimized therapeutic response prediction.
September 2025: Increasing collaborations between medical device manufacturers, healthcare organizations, and neuroscience research institutes accelerated innovation in the Vagus Nerve Stimulators market worldwide. Strategic partnerships focused on implantable devices, wearable neurostimulation systems, and advanced neuromodulation software platforms.
August 2025: Growing prevalence of neurological and psychiatric disorders strengthened demand for vagus nerve stimulation therapies globally. Governments and healthcare organizations expanded investments in advanced neurotechnology solutions and non-pharmacological treatment approaches to improve long-term patient management.
July 2025: Rising demand for non-invasive stimulation devices and home-based neuromodulation solutions accelerated innovation in wearable vagus nerve stimulation technologies worldwide. Companies increasingly focused on portable devices supporting stress management, sleep improvement, autonomic regulation, and mental wellness applications.
June 2025: Increasing focus on precision neuromodulation, minimally invasive therapies, and digital healthcare integration supported strong growth in the global Vagus Nerve Stimulators market. North America maintained market leadership due to advanced neurotechnology adoption and strong clinical research infrastructure, while Asia-Pacific emerged as a rapidly growing region driven by expanding healthcare investments and rising neurological disease prevalence.
Companies and Competitive Landscape
Key players in the vagus nerve stimulators market include Medtronic PLC, Electrocore LLC, Livanova PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Biocontrol Medical, Bioness Inc., Enteromedics Inc., Nevro Corporation, and Neuropace Inc.
The key players are adopting strategies such as mergers and acquisitions, partnerships, and regional expansion to stand out as strong competitors in the market. New product launches along with an increased focus on R&D are other ways the leading players improve their market presence. For instance, In November 2018, ElectroCore, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded label for gammaCore [non-invasive vagus nerve stimulator (nVNS)] therapy for adjunctive use for the preventive treatment of cluster headache in adult patients.
Trending Reports:
